Anorexia nervosa
Drug research and approvals for anorexia nervosa: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 74 studies of anorexia nervosa are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 74
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Specialist Supportive Clinical Management (SSCM) for Children and Adolescents With Anorexia Nervosa and Atypical…NCT07893145 · Not applicable · Karolinska Institutet · starts May 15, 2026
- Identifying Multidimensional Signatures of Gastric Interoception in Functional DyspepsiaNCT07772167 · Not applicable · Massachusetts General Hospital · starts Mar 16, 2026
- Online FBT-DBT Caregiver Intervention for Caregivers of Individuals With Anorexia NervosaNCT07734779 · Not applicable · Shanghai Mental Health Center · starts Apr 3, 2026
- Eating Disorder Dynamic InterventionNCT07600671 · Not applicable · Trustees of Dartmouth College · starts Jul 8, 2026
- Hormonal And Metabolic Signatures In Human Hypothalamic Neurons In Anorexia NervosaNCT07580209 · Not reported · Maria Miletta · starts Apr 30, 2026
- Incorporating Narrative Into the Treatment of Youth With Anorexia Nervosa (Virtual)NCT07579442 · Not applicable · University of California, San Francisco · starts Oct 2, 2026
- Cognitive Evaluation of Patients With Eating DisordersNCT07478510 · Not reported · Istituti Clinici Scientifici Maugeri SpA · starts Nov 26, 2024
- Feasibility and Acceptability of Metacognitive Training for Eating Disorders in Adolescents With Anorexia NervosaNCT07435818 · Not applicable · University of Évora · starts Mar 2, 2026
- Study of the Effectiveness of a Systematic Minimal Early Intervention on Care Engagement in Adults With Eating…NCT07411807 · Not applicable · Centre Hospitalier St Anne · starts Dec 29, 2025
Phase 3 7
- Estrogens, conjugatedEstrogen receptor agonist
- Prasterone
- Ethinyl estradiolEstrogen receptor alpha agonist
- AripiprazoleDopamine D2 receptor partial agonist
- DenosumabTumor necrosis factor ligand superfamily member 11 inhibitor
- LevonorgestrelProgesterone receptor agonist
- DronabinolCannabinoid CB1 receptor agonist
Phase 2 10
- PsilocybinSerotonin 2a (5-HT2a) receptor agonist
- OlanzapineSerotonin 2a (5-HT2a) receptor antagonist
- Dienogest
- MetreleptinLeptin receptor agonist
- MirtazapineSerotonin 2a (5-HT2a) receptor antagonist
- ProgesteroneProgesterone receptor agonist
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- TestosteroneAndrogen Receptor agonist
- Risedronic acidFarnesyl diphosphate synthase inhibitor
- MidomafetamineSodium-dependent dopamine transporter releasing agent
Phase 1 or earlier 7
- MecaserminInsulin-like growth factor I receptor agonist
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- OxytocinOxytocin receptor agonist
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- BromocriptineD2-like dopamine receptor agonist
- CannabidiolCannabinoid CB1 receptor negative allosteric modulator
- AmisulprideSerotonin (5-HT) receptor antagonist
How its trials ended
402 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 65 whose ending is known, 34% met their primary endpoint, 11% missed it and 55% stopped early.
- Completed, result not reported15940%
- Ongoing12832%
- Status unknown5012%
- Stopped: other or unclear236%
- Met its primary endpoint225%
- Stopped: enrollment or feasibility82%
- Missed its primary endpoint72%
- Stopped: sponsor or business decision2<1%
- Stopped: funding2<1%
- Stopped: lack of efficacy1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA